A pyruvate-buffered dialysis fluid induces less peritoneal angiogenesis and fibrosis than a conventional solution

Peritoneal Dialysis International

Volumn 28, Issue 5, 2008, Pages 487-496

  van Westrhenen, Roos ^a   Zweers, Machteld M ^a   Kunne, Cindy ^a   de Waart, Dirk R ^a   van der Wal, Allard C ^a   Krediet, Raymond T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Peritoneal fibrosis; Polyol pathway; Pseudohypoxia; Pyruvate

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALPHA SMOOTH MUSCLE ACTIN; BUFFER; CREATININE; DIANEAL; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PYRUVIC ACID; SODIUM; VASCULOTROPIN; HEMODIALYSIS FLUID; LACTIC ACID DERIVATIVE; PYRUVIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSATE LEVEL; DIALYSIS; DISEASE SEVERITY; EFFLUENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LACTATE BLOOD LEVEL; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OMENTUM; OUTCOME ASSESSMENT; PERITONEAL CAVITY; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SODIUM BLOOD LEVEL; TREATMENT DURATION; WISTAR RAT; ANIMAL; METABOLISM; METHODOLOGY; PATHOLOGY; PERITONEAL DIALYSIS; PERITONEUM; TRANSPORT AT THE CELLULAR LEVEL; ULTRAFILTRATION; VASCULARIZATION;

ANIMALS; BIOLOGICAL TRANSPORT; FIBROSIS; HEMODIALYSIS SOLUTIONS; IMMUNOHISTOCHEMISTRY; LACTATES; MALE; PERITONEAL DIALYSIS; PERITONEUM; PYRUVATES; RATS; RATS, WISTAR; ULTRAFILTRATION;

EID: 58249087515     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802800512     Document Type: Article

References (53)

1. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
2. Davies SJ. Longitudinal relationships between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66:2437-45.
3. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4): S22-42.
4. Mateijsen MAM, van der Wal AC, Hendriks PMEM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
5. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallen M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
6. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rehrborn A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl 2001; 78:S42-7.
7. Zweers MM, Splint LJ, Krediet RT, Struijk DG. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16:651-4.
8. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urahani K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal mesothelial cells in peritoneal dialysis. FEBS Lett 1999; 17:260-4.
9. Schlingemann RO, van Hinsbergh VW. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br J Ophthalmol 1997; 81:501-12.
10. Alvarez-Arroyo MV, Caramelo C, Angeles Castilla M, Gonzalez Pacheco FR, Martin O, Arias J. Role of vascular endothelial growth factor in the response to vessel injury. Kidney Int Suppl 1998; 68:S7-9.
11. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99:2192-202.
12. Williamson JR, Osrow E, Eades D, Chang K, Allison W, Kilo C. Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor. J Clin Invest 1990; 85: 1167-72.
13. Morrisey K, Steadman R, Williams JD, Philips AO. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int 1999; 55:160-7.
14. Philips AO, Morrisey K, Steadman R, Williams J. Decreased degradation of collagen and fibronectin following exposure of proximal cells to glucose. Exp Nephrol 1999; 7:449-62.
15. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42:801-13.
16. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999; 134:124-32.
17. Zweers MM, Struijk DG, Smit W, Krediet RT. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 2001; 137:125-32.
18. Krediet RT, van Westrhenen R, Zweers MM, Struijk DG. Clinical advantages of new peritoneal dialysis solutions. Nephrol Dial Transplant 2002; 17(Suppl 3):16-18.
19. Kientsch-Engel RI, Siess EA. D-(-)-3-hydroxybutyrate and acetoacetate. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. 3rd ed. Vol. 7. Weinheim: VHC Verlag; 1983: 60-9.
20. Pannekeet MM, Imholz AL, Struijk DG, Koomen GC, Langedijk MJ, Schouten N, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866-75.
21. Zweers MM, Splint LJ, Krediet RT, Struijk DG. Effect of fluid supplementation and modality on peritoneal permeability characteristics in a rat peritoneal dialysis model. Perit Dial Int 2001; 21:58-64.
22. Koomen GCM, Krediet RT, Leegwater ACJ, Struijk DG, Arisz L, Hoek FJ. A fast reliable method for the measurement of intra-peritoneal dextran 70, used to calculate lymphatic absorption. Adv Perit Dial 1991; 7:10-14.
23. Zemel D, Imholz ALT, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-α and soluble TNF receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
24. Krediet RT, Struijk DG, Koomen GC, Arisz L. Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans 1991; 37:662-7.
25. Waniewski J, Werynski A, Heimburger O, Lindholm B. Simple models for description of small-solute transport in peritoneal dialysis. Blood Purif 1991; 9:129-41.
26. Zweers MM, Imholz AL, Struijk DG, Krediet RT. Correction of sodium sieving for diffusion from the circulation. Adv Perit Dial 1999; 15:65-72.
27. Westrhenen van R, de Waart DR, Akman S, Krediet RT. Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurement. Perit Dial Int 2004; 24:290-2.
28. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Zeeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
29. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18:2629-37.
30. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
31. Brunkhorst R, Mahiout A. Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured human mesothelial cells. Kidney Int 1995; 48:177-81.
32. Shostak A, Gotloib L, Kushnier R, Wajsbrot V. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2mM hydrogen peroxide. Nephron 2000; 84:362-6.
33. Ing TS, Zhou XJ, Yu AW, Zhou FQ, Vaziri ND. Effects of pyruvate-based or lactate-based peritoneal dialysis solutions on neutrophil intracellular pH. Int J Artif Organs 1997; 20:255-60.
34. Wu YT, Wu ZL, Jiang XF, Li S, Zhou FQ. Pyruvate preserves neutrophilic superoxide production in acidic, high glucose-enriched peritoneal dialysis solutions. Artificial Organs 2003; 27:276-81.
35. Wy YT, Wu ZL, Jiang Y-F, Li S, Zhou FQ. Pyruvate improves neutrophilic nitric oxide generation in peritoneal dialysis solutions. Artificial Organs 2005; 29:976-80.
36. Mahiout A, Brunkhorst R. Pyruvate anions in peritoneal dialysate solutions preserve the function of peripheral and peritoneal leukocytes in vitro. Nephrol Dial Transplant 1995; 10:391-4.
37. Musi B, Carlsson O, Rippe A, Wieslander A, Rippe B. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998; 18:303-10.
38. Albrechtsson A, Bazargoni F, Wieslander A, Braide A. Peritoneal dialysis fluid-induced angiogenesis in rat mesentery is increased by lactate in the presence or absence of glucose. ASAIO J 2006; 52:276-81.
39. Zweers MM, de Waart DR, van der Wal AC, Dekker FW, Krediet RT, Struijk DG. Structural and functional changes of the peritoneum in a chronic peritoneal infusion model in the rat. In: Zweers MM, ed. Experimental and Clinical Studies on Peritoneal Physiology and Morphology During Chronic Peritoneal Dialysis [Thesis]. University of Amsterdam; 2000: 77-96.
40. Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT. Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 1993; 43:1339-46.
41. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased peritoneal surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-22.
42. Pietrzak I, Hirszel P, Shostak A, Welch PG, Lee RE, Maher JF. Splanchnic volume, not flow rate determines peritoneal permeability. ASAIO Trans 1989; 35:583-7.
43. Wong TY, Philips AO, Witowski J, Topley N. Glucose-mediated induction of TGFbeta1 and MRCP 1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int 2003; 63:1404-16.
44. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62:697-703.
45. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
46. Honda K, Nitta K, Horitas S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999; 14:1541-9.
47. Miayata T, Horie K, Keda Y, Fujita Y, Izuhara Y, Hirano H, et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-35.
48. Devuyst O, van Ypersele de Strihou C. Nitric oxide, advanced glycation end products, and uremia. Kidney Int 2000; 4:1814-15.
49. Van Erven DMM, Gabreëls FJM, Wevers RA, Doesburg WH, Ruitenbeek W, Renier WO, et al. Intravenous pyruvate loading test in Leigh syndrome. J Neurol Sci 1987; 77:217-27.
50. Kristo G, Yoshimura Y, Niu J, Keith BJ, Mentzer RM Jr, Lasley RD. The intermediary metabolite pyruvate attenuates stunning and reduces infarct size in vivo porcine myocardium. Am J Physiol Heart Circ Physiol 2004; 286: H517-H524.
51. Hermann HP, Arp J, Pieske B, Kogler H, Baron S, Janssen PML, et al. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 2004; 6:213-18.
52. Olivencia-Yurvati AH, Blair JL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during surgery with cardio-pulmonary bypass. J Cardiothorac Vasc Anesth 2003; 17: 715-20.
53. Mallet RT, Sun J, Knott ME, Sharma AB, Olivencia-Yurvati AH. Metabolic cardioprotection by pyruvate: recent progress. Exp Biol Med 2005; 230:435-43.